{
  "doc_id": "bed240212_imjudo_4104-2022",
  "created_date": "2024",
  "country": "SE",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Imjudo Imjudo (treme binatio (50 50 mg/ml)",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Evaluated indication",
      "text": "o o limumab__) __ __ MEDTERM1__) , solution 20 mg/carcinoma carcinoma (HCC ag: 2024-behandli behandli C). e. e. adult",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Medicine Medicine Mission",
      "text": "Agency Agency (TLV) Working group: Johan Stengård (investigator), Nima Salari (senior medical investigator), Ida Ahlin (health economist) Ahlstedt Ahlstedt (lawyer) Clinical expert: on. on. Company: AstraZeneca Diary number: 4104/2022 Postal address: Visiting Visiting address: Stockholm Stockholm Phone: 4 4 Stockholm",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "ii",
      "text": "and and price-The The price-of of price-term term \"list price\" terms terms \"net cost\", \"treatment cost\", after after delivery' used. used. electricity/per per package/used. used. nad/given given period/cycle.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "and and summary",
      "text": "• Tecentriq Tecentriq (_MEDTERM4_) Lenvima Lenvima (__ITTERM7__). • Imfiniq Imfiniq (_atezolizumab) TEcentriq TEcentriq (_ITDEM4_), plus _$the the patient'as as follows: • comparator. comparator. • In TLV'Lenvima. Lenvima. • plus plus _$results results ....................... gnde ...........athen.........",
      "start_page": 4,
      "end_page": 5
    },
    {
      "heading": "1 Background",
      "text": "number number 1219/cancer cancer (_MEDTERM0__) of of ≥ 1% cancer. cancer.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Hepatocellular Hepatocellular cancer",
      "text": "cells cells (hepatocytes). erythrocytes. erythrocytes. [1] viruses viruses (and and C), damage damage (alcohol and aflatoxin) diseases diseases (haemochromatos, haemochromatos, porfyria). potential potential (hypatitis and ablatoxin) disorders disorders (prphyria. prphyria.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Medicinal Medicinal products",
      "text": "2023 2023 . company. company.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Indication",
      "text": "cancer. cancer.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Mechanism of action",
      "text": "immune immune system'increasing increasing T- proliferation. proliferation. [2,3] blocks blocks PD- production. production.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Dosage/administration",
      "text": "toxicity toxicity [3]. tolerance tolerance [3]. Imfinzi Imfinzi [3]. infusion infusion [3, 4]. STRIDE STRIDE (Inter-choice Inter-choice __). STRIDE. STRIDE.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Current treatment recommendations",
      "text": "regimen. regimen.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Comparison Options",
      "text": "according according to: 5-6 = 7-9 7-9 = and and > 9 = impairment. impairment. • etiology etiology • to to STRIDE: • non-villal non-villal ethiology: __ MedTERM 0__+ __",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "TLV Discussion",
      "text": "to to TLV'to to TLF'with with _$MEDTERMM0__+ to to 75% publication publication [5]. therapeutic therapeutic salts- TLV TLV assessment: assessed assessed as: - be_MEDERTERM1_____ be_MEDERTERM1_____ (__ __ MEDTERM5__+ not not appropriate) - ____MEDTERMS2__ (with with _MEDTERMM0_",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "and and safety",
      "text": "HIMALAYA HIMALAYA [6] 2024 2024 [7].",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "Method",
      "text": "B. B.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Results",
      "text": "months months (95% 2-19. 2-19.6) months months (95%3-16. 3-16.1) in the _$months months (95-1.6) 1 1 (0.78; 95% 66-0. 66-0.62). of of STRIDE'MedTERM7. MedTERM7.",
      "start_page": 9,
      "end_page": 13
    },
    {
      "heading": "Unwanted Events [6]",
      "text": "the the __MEDTERM0_ar- 20. 20.1% 1. 1.9% arm. arm.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "TLV Discussion",
      "text": "the the study'sorafenib sorafenib [2]. TLV'period. period.",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "TLV assessment:",
      "text": "against against atezolizumab+ surveys. surveys.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "difference difference in",
      "text": "5. 5.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "plus plus bevaci-",
      "text": "did did [------ ------...----], 6. 6.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "including including [------ -----------]",
      "text": "30. 30. § plus plus bevaci- for for __METRM0_+IMbrave150 IMbrave150 [5]. for for _$was was [------ ------...----] company. company.",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "that that PFS",
      "text": "7. 7.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "plus plus bevaci-",
      "text": "zumabfrom IMbrave150",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "in in sub-grup-",
      "text": "were were [------ ------...----] subgroup. subgroup.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "TLV Discussion",
      "text": "to to indi- metaanalyses metaanalyses [16, 17] the the company'remained remained in:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "of of atezoli-",
      "text": "wide. wide.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "were were available",
      "text": "months. months.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "__MEDTERM0_versus __ MEDTERM1__). STRIDE STRIDE and",
      "text": "to to atezoli- being being TLV'options. options. TLV: the the company'for for __MIDEM0_+ plus plus _$__MINTERM10. __MINTERM10.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "to to lenvatinib",
      "text": "REFLECT REFLECT [10], of of _$of of HIMALYA:was was [-------2-----2-. the the CITES_79_ELD_",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "to to [----------- ------]",
      "text": "became became [------ ------]]. to to sorafe- 65 65 (95% 56-0. 56-0.77). calculated. calculated.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "to to [------ -----------] indicating significantly",
      "text": "PFS_. PFS_.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "TLV Discussion",
      "text": "met met [10]. months months (95 95 % 57-0. 57-0.77) [10] equivalent. equivalent.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "company company has:",
      "text": "comparison. comparison. TLV's assessment: had had __ITTERM0__[----] a a STRIDE-__INTERM1. __INTERM1.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "__ITTERM2__, __ITTERM2__,",
      "text": "and and _$__MEMBER6_ __MEMBER6_ than",
      "start_page": 17,
      "end_page": 18
    },
    {
      "heading": "3 Health economy",
      "text": "uncertain. uncertain.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Clinical efficacy",
      "text": "the the company's MAIC (4. 4.3). estimates. estimates.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Overall Survival",
      "text": "In the company'the the ‘BODY_TRM3___ for STRIDE' containing containing __ITTERM0__- the the period'3 3 knots; Odds 1 knot; ODDs 2 nodes; log-logistic; Gomperstz, generalised gamma; knots. knots.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Progression-Free Survival",
      "text": "distribution distribution [------ ------...---------] allocation allocation [--–----—----...\" if if [---] ([----2----- ---- ]) the the company'30. 30.",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "TLV Discussion",
      "text": "The TLV:the the company'is is 98% is is 10%. the the patient'arms arms (HR=1). still still pro-the the patient'period. period. __MEDTERM_28_TERM_33_EN_EN/EN_ITER_EN",
      "start_page": 21,
      "end_page": 24
    },
    {
      "heading": "of of life",
      "text": "with with EQ-al al [11] Brazier Brazier [12]. the the company'arms. arms.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "STRIDE [----] [---] [---]",
      "text": "Sorafenib and [----] [---] [---] (----) Lenvima",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "TLV Discussion",
      "text": "the the quality-utility utility values: 2010. 2010. 13(5): sorafenib sorafenib [2] TLV TLV assessment: to to EQ-Dolan. Dolan.",
      "start_page": 24,
      "end_page": 25
    },
    {
      "heading": "the the medicine",
      "text": "mg mg (mg mg tablets) study study [10] where 68% and and 32% not not 100% intensity intensity (RDI) the the company'4 4 (pack size – week week play) fell 50 mg/ml; ml ml (kr kr 98% kr kr vial) mg mg /ml; 10 ml (kr kr 98% kr kr vial) mg mg (1 vial) 100% mg mg (per tablet) Lenvima Lenvima 100% kr kr (30 tablets) kr 78% kr kr (112 tablets) per per tablet)",
      "start_page": 25,
      "end_page": 26
    },
    {
      "heading": "resource resource utilisation",
      "text": "[THR]-% [TRM-%]",
      "start_page": 26,
      "end_page": 27
    },
    {
      "heading": "and and Lenvima",
      "text": "Progression-free [------] kr [--...--] disease disease [-- ----]",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "Other direct costs",
      "text": "to to TLV'Tecentriq Tecentriq (ref. no. 2440/2019). detail. detail.",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "TLV Discussion",
      "text": "REFLECT REFLECT [10]. of of TLV'the the patient'is is 88% TLV TLV [10]. MedTERM38__ MedTERM38__ (HR 0.66) to to __CONTERM01___'in in TLV'___MEDTERMM38_ ___MEDTERMM38_ '-STRIDE, STRIDE, __PERM0$__/the the patient'treatment. treatment.TLV_MQ_CWH_DWY_DY_TWYL_TQ_TYL-TYN_TXL_FY_SYL=the the patient'3 3 mg/2 2 mg/in in TLV's analysis",
      "start_page": 27,
      "end_page": 31
    },
    {
      "heading": "4 Results",
      "text": "the the company'etiologi. etiologi.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "the the company's baseline scenario",
      "text": "the the company'analysis. analysis. •distribution distribution [------ -----------] allocation allocation [--—----...---- 6-----; and and Imjudo'MedTERM4. MedTERM4.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "the the company's baseline scenario",
      "text": "the the company'__ITTERM3___ __ITTERM3___ Increase/SEK SEK -year year (LY) (undiscounted) QAlys QAlys (discountabled) 3.",
      "start_page": 32,
      "end_page": 33
    },
    {
      "heading": "The company's sensitivity analysis",
      "text": "analyses analyses +/- Cost +/- weights weights [------ --are are [--ltentive ltentive Increase/kr kr -non-viral non-viral ethicateurity/minn [-6-440 kr -3] failure failure (CW) 1000 1000 mg/treatment. treatment. • in in TLV'MEDTERM16__ MEDTERM16__ Increase/year year (LY) (undisdiscounted) QALYs QALYs (discountabled) year year (LY) 2 .",
      "start_page": 33,
      "end_page": 36
    },
    {
      "heading": "analyses analyses in:",
      "text": "duration duration (TTD). cr3_k3_c0_k4_kl_k1_k2 cr3_k3_c0_k4_kl_k1_k2 kb_kt_k00_k8_kb_j_kp_kw_k_kx_kv_km_kg_kd_kB_kJK_kL_ch_kh_kf_kTch_zp_j=kl=k_jp_y_kn_kq_ktr_kpr_k-kl/klC_s_kN_j = kn_j._jc_k10_kWh_j6_k32_k+k_g_j,k_(kl)_k20_k 10 % _ph_pp_r_pw_pd_ps_pN_pT_pK_p-p_ _ph_pp_r_pw_pd_ps_pN_pT_pK_p-p_ pt_en_pB_p) __pnn_pth_pmm_pHQ_Pn_p3_(pt)_p rt_eq_p=pt kr1-k3-k0-k8-k2 - k3-c3-K4-k5-k6-k9-k4-K8-K3-C3-1k3 TLV'is is [---] Imfinzi Imfinzi + Tecentriq Tecentriq + SEK SEK - 276. 276.",
      "start_page": 36,
      "end_page": 38
    },
    {
      "heading": "price price levels",
      "text": "Imjudo. Imjudo.",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "levels levels (million SEK) by Im",
      "text": "a a case-Union. Union.",
      "start_page": 38,
      "end_page": 39
    },
    {
      "heading": "the the results",
      "text": "plus plus bevaci- of of quality-results. results.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Budgetary Budgetary impact",
      "text": "that that [----] SEK SEK [-- -----------]",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "the the results",
      "text": "Tecentreriq Tecentreriq + be be [--] in in TLV'_MEDTERMS8_ _MEDTERMS8_ , be be (--) fact fact that:",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "5 References",
      "text": "‘Created_Mester_3', ‘Chemical body',‘Chemoidal cancer', 'Chemecter-in-law', and ‘Chrendar-infectors';",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "heading heading <ii>",
      "text": "Row 1: Agency Agency (TLV) Row Row 2: Row Row 3: Row Row 4: Row 5: Row Row 6: things things TLV'Row Row 7:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <ii> (from previous page)",
      "text": "Row 1: The term \"list price\" Row Row 2: medicine medicine ef- terms terms \"net cost\", \"treatment cost\"/ \"reimbursement\" are not used; Row 3: \"medicinal medicinal product/consumer item price\" per per package/Row Row 4: \"pharmaceutical cost/ cost of use\" given given period/cycle. Row 5: \"TLV\" of of \"drug cost\" + \"administration cost\". cost. cost.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <ii> (from previous page)",
      "text": "Row 1: The pharmacy'the the pre- price. price.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <ii> (from previous page)",
      "text": "Row 1: TLV TLV (not classified).Row Row 2: The company's price",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <ii> (column column 3)",
      "text": "Row 1: Row Row 2: treatment treatment cost/Row Row 3: per per package/Row Row 4: certain certain period/cycle. Row 5: cost cost + cost. cost.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <ii> (column column 3)",
      "text": "Row 1: TLV TLV (not classified).Row Row 2: confidential. confidential.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Heading Heading <TLV Discussion>",
      "text": "Row 1:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Heading Heading < the the drug>",
      "text": "equal equal to: .0whd 1: 中Styrk2Price per",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Heading Heading <resource resource utilisation>",
      "text": "Row 1:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Heading Heading <resource resource utilisation> (column 1)",
      "text": "Row 1: Row Row 2: Tecentriq (_MEDERM2__)",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Heading Heading <TLV Discussion>",
      "text": "Row 1: __MEDTERM0_",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "Heading Heading <TLV Discussion>",
      "text": "Row 1: Row Row 2: Progression-Free",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "Heading Heading <TLV Discussion> (from Previous Page)",
      "text": "Row 1:",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "heading heading <the the company's baseline scenario>",
      "text": "Row 1:",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analysis>",
      "text": "Row 1: Life Life (LY) (undiscounted)",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analysis>",
      "text": "Row1:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analysis>",
      "text": "Row 1:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analysis>",
      "text": "-------un-?-sk----...----d----out-of-s----turn-out-----?-your-key-one-?--?--non-?—?-?–?-d_----",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 1)",
      "text": "Row 1: Life year (LY) (undiscounted)",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 1)",
      "text": "Row 1:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 1)",
      "text": "Row 1:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 1)",
      "text": "------------—---- ------–---- –----",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 2)",
      "text": "Row 1: 中Increasing/reducement",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 2)",
      "text": "Row 1: Increase/reduce",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 2)",
      "text": "Row 1: Cost/QALY",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (column 3)",
      "text": "Row 1: ng",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (from Previous Page)",
      "text": "Row 1: . . ..------...---- -----------469 469 kr",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (from Previous Page)",
      "text": "-------cd_?-sk----?-?-de-?-- of of emotion-tal??- our ourselves-?— our sense-of-need-???--...-- our we---- our best-ight-turn-and-t-- our----our-th-th-- our–-- our-st--?----key-c----ally-c duty-?ow-out-of–---- across-in-the-ate---- my---- key-int-and----—---- ------...----- intra-th and---- –---- about---- 10-----+----",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (from Previous Page)",
      "text": "-------cd----?-sk----...--_----your---- then----turn-----un----out-of-,--?--?—?--",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 1)",
      "text": "Row 1: . . . .",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 2)",
      "text": "Row 1: Dear Row 2:",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 3)",
      "text": "Row 1: Dense Row 2:",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 4)",
      "text": "Row 1: ------------ ------",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 4)",
      "text": "------------ ------",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 4)",
      "text": "------------ ------–----",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 5)",
      "text": "Row 1: 中+/- QALs/-QALs",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (Column Column 7)",
      "text": "Row 1: Cost/QALY",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "Heading Heading < Company Sensitivity Analyses> (from Previous Page)",
      "text": "Row 1:",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "heading heading <analyses analyses i>",
      "text": "Row 1: Row Row 2: 275 275 SEK",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i>",
      "text": "Row 1:",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i>",
      "text": "fall fall of: a a k",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i> (column 1)",
      "text": "Row 1: Row Row 2: won won QALY",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i> (column 1)",
      "text": "Row 1:",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i> (column 1)",
      "text": "Ocht",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i> (column 2)",
      "text": "Row 1: Cost/QALY",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i> (column 3)",
      "text": "Row 1: g",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "heading heading <analyses analyses i> (from previous page)",
      "text": "Row 1: of of Imjudo",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (from previous page)",
      "text": "a a kender? over. over.(c)",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (from previous page)",
      "text": "Row 1:",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 1)",
      "text": "Row 1: Sensitive",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 2)",
      "text": "Row 1: Ghetsanalyses Row 2:",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 2)",
      "text": "Row 1:",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 3)",
      "text": "Row 1: Row Row 2: Row Row 3: 734 734 kr",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 3)",
      "text": "Row 1: +/- Expenses Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: Row Row 8: Row Row 9: Row Row 10: Row Row 11: Row Row 12: Low Low 13: row row 14: Row Row 15: Row Row 16: Row Row 17: Row Row 18: Row Row 19: Row Row 20: 937 783 kr",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 3)",
      "text": "Row 1: stnad",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 4)",
      "text": "Row 1: +/- QALY中+/-QALY",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 5)",
      "text": "Row 1: Row Row 2: Row Row 3: 861 861 kr",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 5)",
      "text": "Row 1: Cost/QALY Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: Row Row 8: Row Row 9: Row Row 10: Row Row 11: Row Row 12: Row Row 13: Row Row 14: Row Row 15: Row Row 16: Row Row 17: Round Round 18: Row Row 19: Row Row 20: 231 231 kr",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 5)",
      "text": "Row 1: total cost",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <analyses analyses i> (column column 6)",
      "text": "Row 1: d",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <levels levels (SEK million) of Im>",
      "text": "Row 1:",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <levels levels (SEK million) of Im>",
      "text": "Row 1:",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <levels levels (million SEK) of Im> (column 1)",
      "text": "Row 1:",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <levels levels (million SEK) of Im> (column 1)",
      "text": "a a nominalktonoveroveroverin:",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <levels levels (million SEK) of Im> (column 2)",
      "text": "Row 1: Row Row 2: Row Row 3: Row 4: Row 5: Row Row 6: Row 7: Row 8: 488 149 kr",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <levels levels (million SEK) of Im> (column 2)",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Row Row 5: 0Row 0Row 6: 25Row 25Row 7: 2Row 2Row 8: 6Row 6Row 9: Row Row 10: Row Row 11: 0, 0,22s",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "Heading Heading <of of Results>",
      "text": "a a primekPchonede",
      "start_page": 39,
      "end_page": 39
    }
  ]
}